Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$67.60

-8.39 (-11.04%)

, BIIB

Biogen

$318.11

-0.21 (-0.07%)

12:42
11/23/16
11/23
12:42
11/23/16
12:42

On The Fly: Top stock stories at midday

The market opened near the new highs achieved yesterday, but has been unable to establish any upward momentum. The stall in the market comes amid a day filled with economic data points. None of them are as highly anticipated as this afternoon's release of the minutes from last month's Federal Reserve policy meeting. The minutes will provide insight as to the committee's feelings about an interest rate hike at their next meeting in December, which the market has been pricing in as a virtual certainty. ECONOMIC NEWS: In the U.S., the MBA mortgage market index rose 5.5% for the week ending November 18. Initial jobless claims rose 18,000 to 251,000 in the week ended November 19, which was just a tick above estimates. Durable goods orders surged 4.8% in October, beating expectations for a 1.5% increase for the month. The FHFA home price index rose 0.6% to 239.2 in September following August's 0.7% increase to 237.9. Markit's manufacturing PMI came in at 53.9 in the flash November reading, slightly above consensus of 53.5. October new home sales of 563,000 were below expectations of 590,000. The University of Michigan consumer sentiment reading climbed 6.6 points to 93.8 in November, after slipping 4 points to 87.2 in October. Crude oil inventories showed a 1.26M barrel draw versus consensus of a 1.0M build. In Europe, November's flash Eurozone PMI composite output index rose to 54.1, which is the best reading of 2016 and an 11-month high. COMPANY NEWS: Shares of Eli Lilly (LLY) have dropped about 11% after the drugmaker announced that a Phase 3 study showed that solanezumab failed to slow loss of cognitive ability in patients with mild Alzheimer's disease. Biogen (BIIB), which is developing its own Alzheimer's drug, also slipped over 4% following the news... Conversely, shares of Deere (DE) have gained 10% after the maker of large farming machinery topped fourth quarter sales and profit expectations. Additionally, the company expects declining sales of farm machinery to start to ease next year... Meanwhile, shares of Juno Therapeutics (JUNO) have plunged more than 26% after the company announced that it has voluntarily placed on hold the Phase 2 clinical trial of JCAR015 after two patients suffered cerebral edema earlier this week and subsequently died. Other companies working on "CAR-T" therapies, a new class of oncology drugs that reengineer a patient's own cells to attack the disease, including Kite Pharma (KITE) and bluebird bio (BLUE), are also falling near noon. MAJOR MOVERS: Among the notable gainers was GameStop (GME), which advanced about 8% after reporting better than expected third quarter earnings per share. Also higher after earnings was Caleres (CAL), which gained over 14% after beating quarterly expectations. Among the noteworthy losers was Nimble Storage (NMBL), which slid over 14% after the company reported in-line third quarter results but provided fourth quarter guidance that came in below expectations. Also lower was Urban Outfitters (URBN), which slipped 9% after the retailer's third quarter results missed profit and sales expectations. Additionally, HP Inc. (HPQ) dropped about 6% despite posting in-line fourth quarter adjusted earnings per share and better than expected revenue for the quarter. However, steady declines in the company's printing business and a weak outlook for 2017 continue to worry investors. INDEXES: Near midday, the Dow was up 22.50, or 0.12%, to 19,046.37, the Nasdaq was down 18.38, or 0.34%, to 5,367.97, and the S&P 500 was down 2.36, or 0.11%, to 2,200.58.

LLY

Eli Lilly

$67.60

-8.39 (-11.04%)

BIIB

Biogen

$318.11

-0.21 (-0.07%)

DE

Deere

$100.99

8.9779 (9.76%)

JUNO

Juno Therapeutics

$29.88

-1.56 (-4.96%)

KITE

Kite Pharma

$51.69

-1.99 (-3.71%)

BLUE

bluebird bio

$60.95

-1.55 (-2.48%)

GME

GameStop

$25.88

1.77 (7.34%)

CAL

Caleres

$32.42

3.9696 (13.95%)

NMBL

Bought by HPE

$8.02

-1.22 (-13.20%)

URBN

Urban Outfitters

$39.01

1.84 (4.95%)

HPQ

HP Inc.

$15.04

-0.915 (-5.74%)

  • 23

    Nov

  • 28

    Nov

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

  • 09

    Jan

LLY Eli Lilly
$67.60

-8.39 (-11.04%)

11/23/16
JEFF
11/23/16
NO CHANGE
Target $100
JEFF
Buy
Eli Lilly still expects to grow revenue, says Jefferies
Jefferies analyst Jeffrey Holford says that while the solanezumab Phase III trial failure is disappointing, Eli Lilly management expects to grow revenue between 2015 and 2020 while expanding margins. Further, the company is still pursuing the Alzheimer's indication though a number of other programs, Holford tells investors in a research note. The analyst previously estimated a negative solanezumab trial outcome could see the stock down $12. Shares of Lilly are currently down $10.19 to $65.80 in pre-market trading. Holford keeps a Buy rating on Lilly with a $100 price target.
11/23/16
JPMS
11/23/16
NO CHANGE
Target $85
JPMS
Overweight
JPMorgan sees 'attractive opportunity' amid Eli Lilly selloff
JPMorgan analyst Chris Schott lowered his price target for Eli Lilly to $85 from $95 after the phase III trial of solanezumab missed on both primary and secondary endpoints. Beyond solanezumab, Lilly has a diverse range of new product opportunities that support 5% sales and mid-teens earnings growth, Schott tells investors in a research note. With the shares down 13% to $65.81 in pre-market trading, the analyst sees an "attractive opportunity." He keeps an Overweight rating on Lilly.
11/23/16
JEFF
11/23/16
NO CHANGE
Target $310
JEFF
Buy
Biogen selloff may be an overreaction, says Jefferies
Jefferies analyst Brian Abrahams believes selloff in shares of Biogen (BIIB) following Eli Lilly's (LLY) Alzheimer's failure may be an overreaction. Signals of activity seen for Lilly's sola "do maintain some possibility" that Biogen's aducanumab could "ultimately make it over the line," Abrahams tells investors in a research note. He keeps a Hold rating on Biogen with a $310 price target, however, viewing the risk/reward as balanced.
11/23/16
SBSH
11/23/16
NO CHANGE
Target $305
SBSH
Buy
Citi sees four reasons why Biogen Alzheimer's drug can still work
Citi analyst Robyn Karnauska sees four reasons why Biogen's (BIIB) Alzheimer's drug aducanumab can still work following the failure of Eli Lilly's (LLY) solanezumab. The analyst lists difference in mechanism of action, efficacy in an end-point-dependent manner, patient population and endpoints as why she thinks Biogen's drug can have a different outcome than Lilly's. The analyst has a Neutral rating on Biogen with a $305 price target.
BIIB Biogen
$318.11

-0.21 (-0.07%)

11/23/16
MSCO
11/23/16
NO CHANGE
MSCO
Overweight
Morgan Stanley expects big reversal today in Biogen shares
Morgan Stanley Matthew Harrison expects shares of Biogen (BIIB) to end the trading day flat or slightly higher. The stock is currently down $26.61, or 8%, to $291.50 in pre-market trading. With Biogen's aducanumab more potent than Eli Lilly's solanezumab, the Alzheimer's drug still has potential for success, Harrison tells investors in a research note. He points out that Lilly management noted that "the study results, including many secondary clinical endpoints, directionally favored solanezumab." Harrison sees hope in the amyloid hypothesis. The analyst has an Overweight rating on Biogen.
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Overweight
Piper's Schimmer proclaims amyloid hypothesis is not dead
Piper Jaffray analyst Joshua Schimmer says the failure of Eli Lilly's (LLY) solanezumab is not the final nail in the amyloid hypothesis coffin. Biogen (BIIB) and Eisai's aducanimab study is the most potent approach for amyloid lowering, Schimmer tells investors in a research note. He points out that he was skeptical whether solanezumab's effect was adequate. "Our view of Alzheimer's for amyloid is informed not so much by the extremely sloppy science in that disease, but by consistent cause/effect signals across other amyloidosis," Schimmer writes. He believes today's selloff in shares of Biogen "creates some breathing room." The analyst recommends looking to build a position in Biogen after the stock settles down. Schimmer reiterates an Overweight rating on the shares with a $335 price target. The stock is down 8%, or $24.41, to $293.70 in pre-market trading.
DE Deere
$100.99

8.9779 (9.76%)

10/31/16
BARD
10/31/16
UPGRADE
Target $100
BARD
Outperform
Deere upgraded to Outperform at Baird
As reported previously, Baird analyst Mircea Dobre raised his rating on Deere to Outperform from Neutral, noting that North American large ag equipment is back to multi-decade lows and there is a sign of demand emerging outside the U.S. and there are meaningful cost savings in the pipeline. Dobre reiterated his Outperform rating and raised his price target to $100 from $86 on Deere shares.
11/11/16
DBAB
11/11/16
NO CHANGE
Target $102
DBAB
Buy
Deustche says infrastructure upside not fully priced into Machinery names
Deutsche Bank analyst Nicole DeBlase expects infrastructure stimulus to be more of a 2018 "earnings tailwind" with legislation unlikely until the spring of 2017 at the earliest. She's skeptical that the rally in Machinery stocks can continue for an extended amount of time, but feels only 50% of the total benefit has been priced in, to date. Caterpillar (CAT) is the best way to play a U.S. infrastructure stimulus, DeBlase tells investors in a research note. She raised her price target for the shares to $102 from $95. The analyst also raised her price target for Buy-rated Oshkosh (OSK) to $72 from $65, for Hold-rated Deere (DE) to $95 from $90 and for Sell-rated CNH Industrial (CNHI) to $7.20 from $6.24.
10/31/16
10/31/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ford (F) upgraded to Neutral from Underperform at Daiwa. 2. Chevron (CVX) upgraded to Conviction Buy from Neutral at Goldman with analyst Neil Mehta saying that after a decade of relatively flat production, the company is positioned for "strong volume improvement." 3. Fossil (FOSL) upgraded to Mixed from Negative at OTR Global with the firm saying checks indicate the response to Michael Kors (KORS) watches has been strong. 4. ADTRAN (ADTN) upgraded to Outperform from Market Perform at Northland with analyst Tim Savageaux citing the share pullback over merger concerns of its top customer CenturyLink (CTL). 5. Deere (DE) upgraded to Outperform from Neutral at Baird with analyst Mircea Dobre saying that North American large ag equipment is back to multi-decade lows and there is a sign of demand emerging outside the U.S. and there are meaningful cost savings in the pipeline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/31/16
BARD
10/31/16
UPGRADE
BARD
Outperform
Deere upgraded to Outperform from Neutral at Baird
JUNO Juno Therapeutics
$29.88

-1.56 (-4.96%)

11/10/16
RHCO
11/10/16
NO CHANGE
RHCO
Juno Therapeutics drug could deliver best in class data, says SunTrust
SunTrust analyst Peter Lawson says that Juno's non-Hodgkin lymphoma,treatment, JCAR017, could deliver best in class data at ASH. The analyst reiterates a $48 price target and a Buy rating on the shares.
11/23/16
JANY
11/23/16
NO CHANGE
JANY
Weakness in bluebird bio unwarranted after Juno trial halt, says Janney Capital
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Piper says CAR-T researchers must heed risks highlighted by Juno news
Piper Jaffray analyst Joshua Schimmer said the CAR-T field has "taken another step back" after Juno Therapeutics (JUNO) put a hold on its JCAR015 trial again due to fatal cerebral edema and cautioned companies exploring these therapies to be mindful of "unnecessarily aggressive development and under-appreciation of the potent and possibly highly toxic nature" of the approach. However, Schimmer expressed his confidence that companies he covers in the CAR-T space - namely bluebird bio (BLUE), Cellectis (CLLS), Celgene (CELG), Bellicum Pharmaceuticals (BLCM), Lion Biotechnologies (LBIO) and NantKwest (NK) - will "respect the power of these platforms and remember patients' lives are more important than stock prices."
11/23/16
11/23/16
NO CHANGE

Buy
bluebird bio weakness unwarranted after Juno trial halt, says Janney Capital
As previously reported, Janney Capital analyst Debjit Chattopadhyay said the weakness in bluebird bio (BLUE) is unwarranted on the heels of Juno's (JUNO) second clinical hold for JCAR015. Chattopadhyay notes several key differences between JCAR015 and bluebird's bb2121, including their targets, diseases, vectors, preconditioning regimens and others. He remains a buyer of bluebird ahead of a "potentially watershed ASH for its lentiglobin platform" and keeps a Buy rating on the stock.
KITE Kite Pharma
$51.69

-1.99 (-3.71%)

11/21/16
HCWC
11/21/16
INITIATION
Target $78
HCWC
Buy
Kite Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Kite Pharma with a Buy rating and $78 price target. While the competition for Chimeric Antigen Receptor T-cells is intense, Kite should have a big first-mover advantage with KTE-C19, Davis tells investors in a research note.
10/10/16
ADAM
10/10/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma BLA filing still expected by year end, says Canaccord
Canaccord analyst John Newman noted Kite Pharma released 12 month update on Zuma-1 Phase 1, which showed durable efficacy and is encouraging despite coming from a small patient group. The analyst saw the release as a continuation of positive trends and expects a BLA filing by the end of 2016. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
11/10/16
RBCM
11/10/16
NO CHANGE
RBCM
Kite Pharma weakness creates buying opportunity, says RBC Capital
After Kite's stock fell recently, RBC Capital analyst Michael Yee blames the pullback on macro worries about the biotech sector and a number of "short-term questions," about several issues, including upcoming ASH data, new durability data expected next quarter, and questions about the FDA's view of its drug. However, the analyst thinks that the company's comments indicate that its talks with the FDA are going well, and he says he remains upbeat on the company's pipeline. He expects "a lot" of concerns about the company to be mitigated in the next three to six m,months, as he thinks that it will report positive data in the near to medium term.The analyst keeps an $85 price target and an Outperform rating on the shares.
BLUE bluebird bio
$60.95

-1.55 (-2.48%)

11/11/16
11/11/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aegerion (AEGN) resumed with a Neutral at JPMorgan. 2. Lamb Weston (LW) initiated with a Buy at Stifel, initiated with an Overweight at Barclays, and an Equal Weight at Morgan Stanley. 3. bluebird bio (BLUE) initiated with a Market Perform at BMO Capital. 4. Alder Biopharmaceuticals (ALDR) initiated with an Outperform at BMO Capital. 5. ACADIA (ACAD) initiated with a Neutral at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
GME GameStop
$25.88

1.77 (7.34%)

11/03/16
BARD
11/03/16
NO CHANGE
Target $25
BARD
Outperform
GameStop price target lowered to $25 from $40 at Baird
Baird analyst Colin Sebastian lowered his price target on GameStop to $25 from $40 following its Q3 preannouncement. The analyst said his field checks indicated mixed pre-order levels for key holiday titles through October and he expects promotional activity to drive holiday demand. Sebastian maintained his Buy rating on GameStop shares as his rating is based on the company's long-term diversification strategy and ongoing free cash flow generation.
11/02/16
PIPR
11/02/16
DOWNGRADE
PIPR
Neutral
GameStop downgraded to Neutral from Overweight at Piper Jaffray
11/11/16
PIPR
11/11/16
NO CHANGE
PIPR
Oct. NPD video game software sales rose 11%, says Piper Jaffray
Piper Jaffray analyst Michael Olson says October NPD video game software sales were up 11% year-over-year due to strong results from incremental launch titles, including Electronic Arts' (EA) Battlefield 1 as well as Take Two's (TTWO) Mafia III, among others. The analyst, however, views the October NPD results as "largely irrelevant" since Activision Blizzard (ATVI), EA and Take-Two already announced December quarter guidance and GameStop (GME) recently announced preliminary October quarter results. He keeps Overweight ratings on all four names.
11/02/16
PIPR
11/02/16
DOWNGRADE
Target $23
PIPR
Neutral
GameStop cut to Neutral on game business erosion at Piper Jaffray
As previously reported, Piper Jaffray analyst Michael Olson, downgraded GameStop to Neutral from Overweight after the company pre-released a quarterly earnings miss and lowered its fiscal year guidance. This quarter will "prove to be a microcosm of the next several years," as the company's core gaming business erosion cannot be offset by growth in its new initiatives, predicted Olson, who lowered his price target on GameStop shares to $23 from $41.
CAL Caleres
$32.42

3.9696 (13.95%)

01/27/16
01/27/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Arista Networks (ANET) initiated with a Buy at Citi... Brocade (BRCD) initiated with a Neutral at Citi... CBL & Associates (CBL) initiated with an Underperform at Boenning & Scattergood... Caleres (CAL) initiated with a Hold at BB&T... Ciena (CIEN) initiated with a Neutral at Citi... Fitbit (FIT) initiated with a Buy, $35 target at Citi... Genesco (GCO) initiated with a Hold at BB&T... Infinera (INFN) initiated with a Buy at Citi... Nabriva Therapeutics (NBRV) initiated with a Buy at Gabelli... SanDisk (SNDK) initiated with a Buy at Citi... Seagate (STX) initiated with a Sell at Citi... Tanger Factory (SKT) initiated with an Underperform at Boenning & Scattergood... Taubman Centers (TCO) initiated with a Neutral at Boenning & Scattergood... WP Glimcher (WPG) initiated with an Underperform at Boenning & Scattergood... Western Digital (WDC) initiated with a Buy at Citi... Yirendai (YRD) initiated with a Buy at Needham.
02/25/16
BUCK
02/25/16
UPGRADE
BUCK
Buy
Caleres upgraded to Buy from Neutral at Buckingham
05/27/16
05/27/16
UPGRADE
Target $26

Buy
Caleres upgraded to Buy from Hold at BB&T
BB&T analyst Corinna Freedman upgraded Caleres due to valuation following the Q1 report and established a $26 price target on shares.
01/27/16
01/27/16
INITIATION

Hold
Caleres initiated with a Hold at BB&T
NMBL Bought by HPE
$8.02

-1.22 (-13.20%)

10/03/16
SUSQ
10/03/16
NO CHANGE
Target $12
SUSQ
Positive
Nimble Storage well positioned to gain market share, says Susquehanna
Susquehanna analyst Mehdi Hosseini believes Nimble Storage remains well positioned to continue to gain market share with its dual faceted approach and material operating leverage on the horizon in 2018. Hosseini reiterated his Positive rating and $12 price target on Nimble Storage shares.
09/29/16
WELS
09/29/16
UPGRADE
WELS
Outperform
Nimble Storage upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Maynard Um upgraded Nimble Storage to Outperform saying the risk/reward is favorable at current valuation levels. A "strong pipeline" for Nimble's all-flash array should drive revenue acceleration in FY18 and multiple expansion, Um tells investors in a research note. The analyst raised his price target range for the shares to $10-$11 from $9-$10.
11/23/16
MAXM
11/23/16
NO CHANGE
Target $12
MAXM
Buy
Nimble Storage shows multiple signs of turnaround progress, says Maxim
Maxim analyst Nehal Chokshi said multiple metrics, including 5K bookings acceleration and SME bookings acceleration, indicate Nimble Storage's turnaround is progressing, which he believes will become more apparent in next quarter. The company's Lenovo deal and R&D pipeline give him further confidence that Nimble will be a long-term storage player, added Chokshi, who keeps a Buy rating and $12 price target on the shares, which are down about 13% to $8.05 in pre-market trading.
11/23/16
SUSQ
11/23/16
NO CHANGE
Target $12
SUSQ
Positive
Nimble Storage takeover prospects cannot be overlooked, says Susquehanna
Susquehanna analyst Mehdi Hosseini noted Nimble Storage reported relatively in-line Q3 results and guidance. The analyst said that was enough to keep his framework intact as he believes the company is well positioned to continue gaining market share with its Hybrid/All-Flash portfolio. Hosseini also said its prospects as a takeover target for a large player should not be overlooked. Hosseini reiterated his Positive rating and $12 price target on Nimble Storage shares.
URBN Urban Outfitters
$39.01

1.84 (4.95%)

11/23/16
JEFF
11/23/16
NO CHANGE
Target $45
JEFF
Buy
Jefferies reiterates Buy on Urban Outfitters after Q3 miss
Jefferies analyst Randal Konik reiterates a Buy rating on Urban Outfitters with a $45 price target following the company's Q3 miss. The analyst remains "encouraged" by the momentum at the Urban Outfitters brand, which he notes is bucking the industry trend with higher store traffic. He sees Anthropologie "finding its way" over the next several quarters.
11/23/16
WDLK
11/23/16
DOWNGRADE
Target $32
WDLK
Hold
Wunderlich downgrades Urban Outfitters on 'anemic' Q3 results
Wunderlich analyst Eric Beder downgraded Urban Outfitters to Hold from Buy saying the retailer's "anemic" Q3 results disproved his entire investment thesis. Sales momentum at Free People and Anthropologie continued to weaken and gross margins remained challenged despite easy comparisons, Beder tells investors in a post-earnings research note. He cut his price target for the shares to $32 from $40. Urban Outfitters is down 11%, or $4.14, to $34.87 in pre-market trading.
11/23/16
BARD
11/23/16
NO CHANGE
Target $38
BARD
Outperform
Urban Outfitters margin outlook murkier than anticipated, says Baird
Baird analyst Mark Altschwager noted Urban Outfitters reported weaker than expected Q3 results as sluggish apparel demand at Anthropologie weighed on consolidated comps and margins. The analyst said the apparel market remains choppy and the margin picture is murkier than anticipated and recommends investors wait for opportunities to build or add to positions in the low $30's and look to trim positions in the high $30's. Altschwager maintained his Outperform rating on Urban Outfitters shares.
11/23/16
STFL
11/23/16
NO CHANGE
STFL
Urban Outfitters long-term outlook still positive, says Stifel
After Urban Outfitters reported lower than expected Q3 EPS, Stifel analyst Richard Jaffe says that weakness at the company's Anthrolopolgie unit hindered the company's results. He thinks that Anthrolopologie's offerings continue to be "weak." Jaffe expects the stock to be pressured in the near-term, but he remains upbeat on the company's outlook, partly due to what he sees as its "strong brand equity" and "significant growth opportunities." He keeps a $40 price target and a Buy rating on the shares.
HPQ HP Inc.
$15.04

-0.915 (-5.74%)

11/23/16
11/23/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CBS (CBS) downgraded to Market Perform from Outperform at BMO Capital with analyst Daniel Salmon citing valuation and his belief that the shares will soon begin to trade based on a potential deal with Viacom (VIA, VIAB). 2. Abercrombie & Fitch (ANF) downgraded to Sell from Hold at Deutsche Bank with analyst Tiffany Kanaga saying the Abercrombie brand turnaround is yet to gain traction. 3. Twitter (TWTR) downgraded to Negative from Mixed at OTR Global. 4. HP Inc. (HPQ) downgraded to Hold from Buy at Jefferies with analyst James Kisner citing valuation and secular challenges for the downgrade. 5. First Solar (FSLR) downgraded to Neutral from Outperform at Macquarie with analyst Gurpreet Gujral citing a lack of catalysts after the company canceled the Series 5 product that was originally scheduled to launch in 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/23/16
JEFF
11/23/16
DOWNGRADE
Target $16.75
JEFF
Hold
HP Inc. downgraded to Hold from Buy at Jefferies
Jefferies analyst James Kisner downgraded HP Inc. to Hold with a $16.75 price target following the company's Q4 results. The analyst cites valuation and secular challenges for the downgrade.
08/25/16
MAXM
08/25/16
DOWNGRADE
Target $15
MAXM
Hold
HP Inc. downgraded to Hold on pressured printing margins at Maxim
As previously reported, Maxim analyst Nehal Chokshi downgraded HP Inc. to Hold from Buy and lowered his price target to $15 from $17, saying that his analysis points to sustained printing supplies pricing pressure despite the refresh of its printer hardware. Chokshi added that he expects the company to lower its FY17 earnings guidance at its Securities Analyst Meeting in October.
10/14/16
BMUR
10/14/16
NO CHANGE
Target $18
BMUR
Buy
HP Inc. new business model conservative, says Brean Capital
Brean Capital analyst Ananda Baruah attended the HP, Inc. analyst day and said although it didn't hold any surprises, he believes the company's new long-term business model remains conservative. The analyst said if the company can execute its model its revenue growth will have to be stronger than stated and its guidance must be conservative. Baruah reiterated his Buy rating and $18 price target on HP, Inc. shares.

TODAY'S FREE FLY STORIES

MOS

Mosaic

$20.87

0.03 (0.14%)

16:18
09/20/17
09/20
16:18
09/20/17
16:18
Hot Stocks
Mosaic reports impact of Hurricane Irma on Q3 business performance »

Mosaic issued an update…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$45.21

1.41 (3.22%)

16:17
09/20/17
09/20
16:17
09/20/17
16:17
Syndicate
Juno Therapeutics files to sell $225M in common stock »

Morgan Stanley and J.P.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSM

Versum Materials

$37.86

0.16 (0.42%)

16:17
09/20/17
09/20
16:17
09/20/17
16:17
Initiation
Versum Materials initiated  »

Versum Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

16:17
09/20/17
09/20
16:17
09/20/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
09/20/17
09/20
16:16
09/20/17
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$45.21

1.41 (3.22%)

16:16
09/20/17
09/20
16:16
09/20/17
16:16
Syndicate
Juno Therapeutics files $225M automatic stock shelf »

Morgan Stanley and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$156.07

-2.66 (-1.68%)

, BSTI

Best Inc.

16:16
09/20/17
09/20
16:16
09/20/17
16:16
General news
On The Fly: Top stock stories for Wednesday »

Stocks were largely on…

AAPL

Apple

$156.07

-2.66 (-1.68%)

BSTI

Best Inc.

BABA

Alibaba

$177.95

-2.12 (-1.18%)

FDX

FedEx

$220.53

4.531 (2.10%)

ADBE

Adobe

$149.96

-6.64 (-4.24%)

GIS

General Mills

$52.17

-3.215 (-5.81%)

CPRT

Copart

$33.86

1.32 (4.06%)

ALNY

Alnylam

$113.78

38.7408 (51.63%)

IONS

Ionis Pharmaceuticals

$53.88

-5.19 (-8.79%)

BBBY

Bed Bath & Beyond

$22.74

-4.29 (-15.87%)

DESP

Despegar.com

CELC

Celcuity

$14.29

14.289 (1,428,900.00%)

ZLAB

Zai Lab

KRYS

Krystal Biotech

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 22

    Oct

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

APC

Anadarko

$44.78

1.02 (2.33%)

16:15
09/20/17
09/20
16:15
09/20/17
16:15
Hot Stocks
Anadarko reaffirms production guidance »

"Separately, we want…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

FCPT

Four Corners Property Trust

$25.32

0.02 (0.08%)

16:14
09/20/17
09/20
16:14
09/20/17
16:14
Hot Stocks
Four Corners Property Trust acquires 41 restaurant properties »

Four Corners Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$44.79

1.03 (2.35%)

16:13
09/20/17
09/20
16:13
09/20/17
16:13
Hot Stocks
Anadarko targets $1B of of share repurchases prior to year-end 2017 »

Speaking about the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

TBPH

Theravance Biopharma

$33.07

0.49 (1.50%)

, GSK

GlaxoSmithKline

$40.17

0.25 (0.63%)

16:12
09/20/17
09/20
16:12
09/20/17
16:12
Hot Stocks
GlaxoSmithKline and Innoviva report positive Phase 3 results of Treleg Ellipta »

Theravance Biopharma…

TBPH

Theravance Biopharma

$33.07

0.49 (1.50%)

GSK

GlaxoSmithKline

$40.17

0.25 (0.63%)

INVA

Innoviva

$13.59

0.08 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 24

    Oct

APC

Anadarko

$44.79

1.025 (2.34%)

16:11
09/20/17
09/20
16:11
09/20/17
16:11
Hot Stocks
Anadarko announces $2.5B share repurchase program »

Anadarko Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

QUAD

Quad/Graphics

$20.16

0.33 (1.66%)

16:11
09/20/17
09/20
16:11
09/20/17
16:11
Hot Stocks
Quad/Graphics awarded $450M contract to print all Bluestem catalogs »

Quad/Graphics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

MLHR

Herman Miller

16:11
09/20/17
09/20
16:11
09/20/17
16:11
Hot Stocks
Breaking Hot Stocks news story on Herman Miller »

Herman Miller reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

STBZ

State Bank Financial

$27.79

0.45 (1.65%)

16:08
09/20/17
09/20
16:08
09/20/17
16:08
Hot Stocks
FDIC approves State Bank Financial, AloStar merger transaction »

State Bank Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

16:07
09/20/17
09/20
16:07
09/20/17
16:07
Hot Stocks
Herman Miller CEO says 'encouraged by the strong level of demand' »

Brian Walker, CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

ARCC

Ares Capital

$15.85

0.035 (0.22%)

16:07
09/20/17
09/20
16:07
09/20/17
16:07
Initiation
Ares Capital initiated  »

Ares Capital initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

16:06
09/20/17
09/20
16:06
09/20/17
16:06
Earnings
Herman Miller sees Q2 EPS 55c-61c, consensus 56c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

MLHR

Herman Miller

16:05
09/20/17
09/20
16:05
09/20/17
16:05
Earnings
Herman Miller reports Q1 adjusted EPS 57c, consensus 57c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

MDXG

MiMedx

$12.34

-0.82 (-6.23%)

16:05
09/20/17
09/20
16:05
09/20/17
16:05
Hot Stocks
MiMedx responds to two "deceptive short seller articles" »

MiMedx Group responded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

LUNA

Luna Innovations

$1.64

0.05 (3.14%)

16:05
09/20/17
09/20
16:05
09/20/17
16:05
Hot Stocks
Luna Innovations announces stock repurchase program »

Luna Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AERI

Aerie Pharmaceuticals

$53.40

-5.2 (-8.87%)

16:03
09/20/17
09/20
16:03
09/20/17
16:03
Hot Stocks
Aerie announces FDA Advisory Committee meeting for Rhopressa 0.02% »

Aerie Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 28

    Feb

AMD

AMD

$13.12

0.04 (0.31%)

, TSLA

Tesla

$375.10

-9.9 (-2.57%)

15:57
09/20/17
09/20
15:57
09/20/17
15:57
Periodicals
Tesla working with AMD on self-driving car AI chip, CNBC says »

Tesla (TSLA) is using AMD…

AMD

AMD

$13.12

0.04 (0.31%)

TSLA

Tesla

$375.10

-9.9 (-2.57%)

NVDA

Nvidia

$187.35

-0.2 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AMD

AMD

$13.12

0.04 (0.31%)

, TSLA

Tesla

$375.10

-9.9 (-2.57%)

15:54
09/20/17
09/20
15:54
09/20/17
15:54
Periodicals
Breaking Periodicals news story on AMD, Tesla »

Tesla working with AMD on…

AMD

AMD

$13.12

0.04 (0.31%)

TSLA

Tesla

$375.10

-9.9 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

15:50
09/20/17
09/20
15:50
09/20/17
15:50
General news
More from Yellen: »

More from Yellen: FOMC…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.